Bit Capital Gmb H Syndax Pharmaceuticals Inc Transaction History

Bit Capital Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$12.52 - $21.81 $1.1 Million - $1.92 Million	-87,997 Closed	0 $0
Q3 2024 Feb 12, 2025	BUY	$17.93 - $24.81 $147,223 - $203,714	8,211 Added 10.29%	87,997 $1.69 Billion
Q2 2024 Feb 12, 2025	BUY	$18.82 - $23.79 $241,310 - $305,035	12,822 Added 19.15%	79,786 $1.64 Billion
Q1 2024 Feb 12, 2025	BUY	$19.71 - $24.57 $1.16 Million - $1.45 Million	58,910 Added 731.44%	66,964 $1.59 Billion
Q4 2023 Feb 12, 2025	SELL	$11.39 - $21.67 $333,111 - $633,760	-29,246 Reduced 78.41%	8,054 $174 Million
Q2 2023 Feb 12, 2025	BUY	$19.35 - $22.31 $229,916 - $265,087	11,882 Added 46.75%	37,300 $781 Million
Q1 2023 Feb 12, 2025	BUY	$20.66 - $28.98 $97,866 - $137,278	4,737 Added 22.91%	25,418 $537 Million
Q4 2022 Feb 12, 2025	SELL	$20.64 - $26.24 $1,651 - $2,099	-80 Reduced 0.39%	20,681 $526 Million
Q3 2022 Feb 12, 2025	BUY	$18.51 - $24.79 $384,286 - $514,665	20,761 New	20,761 $499 Million

232

93.8M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $849M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

Stay updated on Bit Capital Gmb H with notifications on news.